Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.47 USD | -1.02% | +2.25% | +2.52% |
Financials (USD)
Sales 2024 * | 143M | Sales 2025 * | 33.68M | Capitalization | 491M |
---|---|---|---|---|---|
Net income 2024 * | -20M | Net income 2025 * | -147M | EV / Sales 2024 * | 2.72 x |
Net cash position 2024 * | 104M | Net cash position 2025 * | 141M | EV / Sales 2025 * | 10.4 x |
P/E ratio 2024 * |
-31.4
x | P/E ratio 2025 * |
-4.08
x | Employees | 160 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.37% |
Latest transcript on Entrada Therapeutics, Inc.
1 day | -1.02% | ||
1 week | +2.25% | ||
1 month | +16.75% | ||
3 months | +12.67% | ||
6 months | +15.45% | ||
Current year | +2.52% |
Managers | Title | Age | Since |
---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 17-07-31 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 20-10-31 |
Nathan Dowden
PSD | President | 54 | 19-11-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 20-11-30 |
Mary Thistle
BRD | Director/Board Member | 64 | 21-05-03 |
Gina Chapman
BRD | Director/Board Member | 57 | 23-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 15.47 | -1.02% | 87,480 |
24-05-30 | 15.63 | +1.56% | 62,774 |
24-05-29 | 15.39 | -4.65% | 94,369 |
24-05-28 | 16.14 | +6.68% | 141,161 |
24-05-24 | 15.13 | +0.73% | 33,861 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.52% | 491M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.67% | 12.27B |
- Stock Market
- Equities
- TRDA Stock